Agilent posted 6.3% core growth, 14% EPS growth, and raised FY26 guidance, but the stock still needs continued execution at 23.0x forward earnings.
Agilent Technologies (A) earns a Buy rating for moderate-risk investors with a medium-term horizon. The thesis rests on three hard facts: fiscal Q2 2026 revenue reached $1.83B, core growth was 6.3%, and non-GAAP EPS rose 14% to $1.49. Management also raised FY26 guidance to $7.39B-$7.49B of revenue and $6.00-$6.10 of non-GAAP EPS.
The operating recovery is gaining quality. Q2 operating margin reached 26.4%, up 130 basis points year over year, while gross margin reached 55.0%. The Ignite operating system contributed approximately 200 basis points of pricing in the quarter, and manufacturing overhead fell by more than 50 basis points versus the prior year.
Agilent combines instruments with consumables, services, software, and diagnostics. Consumables represented 66% of Q2 revenue and services represented 34%, creating a broader recurring-revenue foundation than a pure equipment vendor. The main constraint is valuation: trailing P/E is 30.8x and forward P/E is 23.0x, so the stock still requires continued earnings execution.
Agilent Technologies (A), headquartered in Santa Clara, California, provides analytical instruments, diagnostics, software, services, and consumables for life sciences, healthcare, environmental, forensic, chemical, and advanced-materials customers. The company was incorporated in 1999, employs approximately 18,000 people, and serves customers in 110 countries.
Agilent reports through three operating groups: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. Fiscal 2025 revenue was $6.95B. CrossLab generated $2.91B, Life Sciences and Diagnostics Markets generated $2.73B, and Applied Markets generated $1.31B.
The geographic base is broad. Fiscal 2025 revenue included $2.81B from the Americas, $1.92B from Europe, and $2.22B from Asia Pacific. In Q2 FY26, the Americas represented 42% of revenue, APAC 30%, and Europe 28%.
Life Sciences and Diagnostics Markets generated Q2 revenue of $732M, up 9% on a core basis. Low double-digit growth in liquid chromatography and liquid chromatography-mass spectrometry, along with double-digit cancer diagnostics growth, drove the result.
Pharmaceutical demand grew 6% in Q2, with biotech delivering low double-digit growth for the third consecutive quarter. Agilent also reported approximately 20% year-to-date growth tied to GLP-1 activity. Advanced Therapeutics delivered high single-digit growth, and management expects mid-teens growth for that division in FY26.
Agilent CrossLab produced Q2 revenue of $759M, up 2% on a core basis. China comparisons were affected by customer consumables stocking before tariffs, while CrossLab grew at the high end of mid-single digits outside China and consumables grew at a high-single-digit rate. CrossLab carried the highest reported operating margin among the three groups at 32.0%.
Applied Markets generated Q2 revenue of $344M, up 11% on a core basis. Spectroscopy delivered double-digit growth on semiconductor production demand, while gas chromatography benefited from a technology refresh cycle. Chemical and Advanced Materials grew 8%, diagnostics and clinical grew 11%, and environmental and forensics grew 13%.
The segment mix gives Agilent several earnings levers. CrossLab supplies recurring consumables and services, Life Sciences and Diagnostics Markets provides exposure to pharma and pathology, and Applied Markets adds semiconductor, chemical, environmental, and forensic demand. Academia and government declined 5% in Q2, while food declined 3%, showing that the recovery is broad but not uniform.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Agilent's flagship analytical platforms are liquid chromatography, liquid chromatography-mass spectrometry, gas chromatography, mass spectrometry, spectroscopy, and associated software. Q2 instrument revenue grew at a high-single-digit rate, with liquid chromatography, liquid chromatography-mass spectrometry, and gas chromatography each delivering low double-digit growth.
The Infinity III liquid chromatography platform and 8850 gas chromatograph are central to the replacement-cycle thesis. Management tied their performance to customers upgrading fleets for higher efficiency and stronger workflow performance. Instrument orders met or exceeded revenue for the ninth consecutive quarter, producing a book-to-bill above 1 in Q2.
The new 9500 triple-quadrupole ICP-MS platform targets throughput, workflow complexity, and operating costs. Its patented dual system increases throughput, its air mode removes the need for dedicated oxygen gas, and its OpenLab ICP-MS software automates method migration. The product addresses advanced materials, mining, food, and environmental laboratories.
New gas chromatographs add oven cooldown speeds of up to 30% faster, built-in performance monitoring, proactive maintenance support, and helium-conservation features. In CrossLab consumables, Altura, Ultra, and Elite columns grew more than 50% sequentially and reached 75% of the top 20 biopharma accounts.
Agilent's competitive advantage comes from the combination of an installed instrument base, validated workflows, application expertise, and recurring consumables and service demand. In regulated pharmaceutical and diagnostic laboratories, replacing an instrument involves workflow changes, employee training, and validation work. That friction supports customer retention when Agilent continues to improve performance.
OpenLab CDS version 3.0 expands workflow integration across chromatography, mass spectrometry, and spectroscopy, including high-resolution mass spectrometry. A unified software layer increases the value of Agilent's installed base and links instrument upgrades with informatics adoption.
The Omnis family is gaining traction in cancer diagnostics, while pathology reagents delivered strong double-digit growth through the expanding instrument base. Agilent's planned Biocare Medical acquisition adds a clinically focused antibody menu and expands its immunohistochemistry and molecular pathology capabilities.
Agilent also announced a collaboration with OpenAI and BCG to accelerate artificial intelligence across the enterprise. Management described AI as a FY26 focus area for customer workflows and internal productivity. The financial evidence is already stronger for operational execution than for direct AI revenue, so the investment case should treat AI as an added product and efficiency lever rather than the core valuation driver.
Ignite is the central operating initiative. In Q2, strategic pricing contributed approximately 200 basis points, exceeding the original full-year goal of 100 basis points on a quarterly run rate. Productivity programs, manufacturing changes, and supply-chain improvements also supported the 130-basis-point year-over-year increase in operating margin.
The company built an AI-enabled supply-chain control tower to improve demand planning, supply calibration, scheduled attainment, order conversion, and cycle times. Management also reported more than 50 basis points of lower manufacturing overhead versus the prior year.
Agilent's tariff task force used manufacturing changes and targeted price adjustments to fully offset the operating-profit impact of incremental tariffs that began in late spring. New digital orders grew 9% in Q2 and more than 20% outside China, adding a lower-cost transaction channel.
The balance between operating leverage and supply-chain exposure remains important. Management cited material shortages, logistics disruption from the Middle East conflict, memory-chip demand, and inflationary costs as pressures on the second half. The current FY26 plan includes approximately $450M of capital expenditures and $1.6B-$1.7B of operating cash flow.
Agilent operates in a life science tools market with several independent size estimates. Mordor Intelligence estimates the global life science tools market at $153.81B in 2025 and $230.07B in 2031, a 6.9% CAGR. MarketsandMarkets estimates the narrower life science instrumentation market at $54.9B in 2023 and $73.9B in 2028, a 6.1% CAGR.
The market is shifting from standalone instruments toward integrated workflows. Demand is growing for high-performance analytical, separation, imaging, automation, software, laboratory information systems, and services across genomics, proteomics, cell therapy, bioprocessing, and formulation development.
Agilent's $83B addressable-market framework includes a $6B Life Sciences and Diagnostics Markets opportunity and a $7B Environmental and Forensics opportunity. FY25 revenue of $6.95B means future expansion relies on share gains, replacement cycles, recurring revenue, product launches, and adjacent markets rather than market growth alone.
Customer spending is still cyclical. Agilent's 2024 revenue decline was tied in part to pressure on customer capital expenditures, while Q2 FY26 showed a recovery in instruments, semiconductor-related demand, pharma, and diagnostics. That pattern supports a recovery thesis but also explains why a premium multiple requires continued execution.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
Agilent serves pharmaceutical and biotech companies, contract development and manufacturing organizations, clinical and pathology laboratories, chemical producers, semiconductor supply chains, food laboratories, environmental agencies, forensic organizations, academia, and government customers.
Pharma and biotech are the largest end-market engine in the current recovery. Q2 pharma grew 6%, biotech grew at a low double-digit rate, and Advanced Therapeutics delivered high single-digit growth. Diagnostics and clinical grew 11%, led by cancer diagnostics, pathology reagents, and companion diagnostic services.
The customer relationship extends beyond the initial equipment sale. CrossLab provides repairs, parts, maintenance, installation, training, compliance support, asset management, consulting, software, columns, sample preparation products, and laboratory supplies. This breadth links customer retention to recurring purchases and service contracts.
Agilent competes with Thermo Fisher Scientific (TMO), Danaher (DHR), Waters (WAT), Bruker (BRKR), Shimadzu, Roche, and other specialists. The company's stated competitive criteria include product performance, reliability, support quality, applications expertise, solution breadth, global channel coverage, and price.
Thermo Fisher and Danaher have greater overall scale and broader portfolios. That scale supports large research budgets, global service infrastructure, and acquisition capacity. Agilent counters with focused strength in chromatography, mass spectrometry, pathology-adjacent diagnostics, CrossLab services, and analytical chemistry.
Waters is a more focused chromatography and mass spectrometry competitor, while Bruker and Shimadzu compete across analytical instruments and spectroscopy. Agilent's advantage is the combination of global reach, consumables, services, software, and workflow integration rather than a single-product monopoly.
The latest operating evidence favors Agilent. Management reported share gains across major geographies, a book-to-bill above 1 for nine consecutive quarters, double-digit growth in several instrument categories, and more than 50% forensics growth supported by a TSA airport security contract and large tender wins in Asia and Europe.
Agilent's end markets respond to pharmaceutical research budgets, industrial capital expenditures, semiconductor production, government funding, and regional procurement conditions. The Q2 pattern was mixed: semiconductor demand and Americas chemical capital spending were strong, while academia and government declined 5% and food declined 3%.
China remains a specific pressure point. China revenue declined 9% in Q2, with funding delays in China and India affecting food demand. Management described first-half China revenue as roughly flat against the prior year and kept the full-year framework intact.
Tariffs and the Middle East conflict add cost and logistics risks. Management reported full mitigation of incremental tariff effects through pricing and manufacturing changes, but also cited material shortages, shipping disruption, and inflationary pressure. The mitigation record is positive; the need to deploy it demonstrates that geopolitical costs remain a recurring operating variable.
Longer-term industry forces are constructive. MarketsandMarkets identifies demand from precision diagnostics, drug development, cell therapy, proteomics, and automation, while Deloitte reports that nearly 60% of life sciences executives plan to increase generative AI investment across the value chain. These forces support Agilent's instruments, software, services, and analytical workflows.
Agilent’s balance sheet earns an A- thanks to a solid capital structure that supports continued investment while the recovery gains traction.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q2 revenue of $1.83B, 6.3% core growth, and a 26.4% operating margin show the income statement is improving on both growth and profitability.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management lifted FY26 guidance to $7.39B-$7.49B of revenue and $6.00-$6.10 of non-GAAP EPS, signaling confidence in the recovery.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Trailing P/E of 30.8x and forward P/E of 23.0x leave Agilent priced for continued earnings execution rather than a deep-value rerating.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →A $160 fair value sits between the $125 Buy level and the $195 Sell level, reflecting solid fundamentals but a still-premium multiple.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Agilent has moved from recovery candidate to credible execution story. Q2 FY26 delivered $1.83B of revenue, 6.3% core growth, $1.49 of non-GAAP EPS, and 26.4% operating margin. The company raised its full-year outlook while absorbing tariff effects and investing in new analytical platforms.
The strongest part of the thesis is the interaction between instruments and recurring revenue. Infinity III LC, 8850 GC, the 9500 ICP-MS, Omnis diagnostics, OpenLab software, columns, services, and pathology reagents all deepen the customer relationship. CrossLab's $2.91B fiscal 2025 revenue and 32.0% Q2 operating margin show why the installed base matters.
A Buy rating is appropriate, but enthusiasm should remain tied to earnings delivery. China, government funding, tariffs, geopolitical logistics, and customer capital spending remain material variables. With a strong balance sheet, rising estimates, and a $160 valuation anchor, Agilent offers a balanced path to medium-term compounding without requiring a speculative AI or diagnostics outcome.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Agilent Technologies, Inc. (A) gains after a stronger-than-expected quarter, with EPS and revenue both topping estimates. Our deep-dive looks beyond the headline beat at end-market momentum, guidance lift, tariff offsets, and the demand signals behind the after-hours move.
Agilent Technologies, Inc. (A) gains after reporting earnings beats, lifting shares 4.0% as investors react to stronger-than-expected quarterly results.
Agilent is regaining growth momentum with stronger margins, rising guidance, and a recurring-revenue mix that supports quality earnings. The stock looks attractive on fundamentals, but valuation leaves less room for execution missteps.